Exhibit 1 Allergan Earnings Release Year Year (unaudited; $ in millions, except per share amounts) Q4 '17 Q4 '17 2017 Q4 '17 Q4'16 Q3 '17 v v Ended December December Ended v Q4 '16 Q3 '17 2016 31, 2017 31, 2016 Total net revenues $ 4,326.10 $3,864.30 $4,034.30 12.0% Operating (Loss) Diluted EPS-Continuing Operations 7.2 % $ 15,940.70 $14,570.60 9.4% $ (90.50) $ 900.00 $(4,022.30)-89.9% -97.8 % $ (5,921.20) $(1,825.50) 224.4% $ 9.97 $ (0.31) $ (12.05) n.m. -182.7% $ (11.99) $ (3.17) 278.2% SG&A Expense $ 1,266.80 $1,276.80 $ 1,169.70 -0.8% $ 408.20 $ 913.30 $ 442.60 -55.3% 8.3 % $ 5,016.70 $4,740.30 5.8% -7.8 % $ 2,100.10 $2,575.70 -18.5% R&D Expense Continuing Operations Tax Rate Non-GAAP Adjusted Operating Income Non-GAAP Performance n.m. 96.4% 29.3% n.m. n.m. 64.2% 67.0% -2.8% $ 2,174.30 $1,868.70 $1,968.20 16.4% 10.5 % $ 7,647.50 $7,245.30 5.6% $ 4.86 $ 3.90 $ 4.15 24.6% 17.1% $ 16.35 $13.51 21.0% Net Income Per Share Non-GAAP Adjusted EBITDA $ 2,284.50 $1,975.70 $ 2,051.70 15.6% 11.3 % $ 8,097.60 $ 7,628.70 6.1% Non-GAAP SG&A Expense $ 1,132.80 $1,067.00 $ 1,099.60 6.2% Non-GAAP R&D Expense $ 405.70 $ 425.90 $ 405.30 -4.7% 3.0 % $ 4,554.80 $ 4,081.70 11.6% 0.1% $ 1,598.80 $ 1,433.80 11.5% Non-GAAP Continuing Operations Tax Rate 11.4% 10.4% 13.1% 1.0% -1.7% 12.6% 8.9% 3.7%